Pleiotropic Effect of Lipoprotein-Apheresis on the Soluble Form of Activated Leukocyte Cell Adhesion Molecule (sALCAM) in Familial Hypercholesterolaemia

Rüdiger von Bauer; Dimitrios Oikonomou; Alba Sulaj; Stefan Kopf; Thomas Fleming; Gottfried Rudofsky; Peter Nawroth

doi:10.1055/a-0630-0232

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2019; 127(05): 276-280
DOI: 10.1055/a-0630-0232

Article

Pleiotropic Effect of Lipoprotein-Apheresis on the Soluble Form of Activated Leukocyte Cell Adhesion Molecule (sALCAM) in Familial Hypercholesterolaemia

Rüdiger von Bauer

¹SRH Kliniken GmbH, Karlsbad, Germany

,

Dimitrios Oikonomou

²Internal Medicine 1 and Clinical Chemistry, University Hospital Heidelberg, Heidelberg, Germany

,

Alba Sulaj

³Internal Medicine I, Universitatsklinikum Heidelberg, Heidelberg, Germany

,

Stefan Kopf

⁴Department of Medicine 1, University of Heidelberg, Heidelberg, Germany

,

Thomas Fleming

⁵University of Heidelberg, Heidelberg, Germany

,

Gottfried Rudofsky

⁶Kantonsspital Olten, Olten, Switzerland

,

Peter Nawroth

⁷Internal Medicine 1 and Clinical Chemistry, UniversitätsKlinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

› Author Affiliations

Abstract

Introduction/Background Atherosclerosis is an inflammatory disorder in which several converging immune responses modulate and induce lipid accumulation in macrophages. Activated leukocyte cell adhesion molecule (ALCAM) has been described as a structural homologue of HDL-receptor and functions as a pattern recognition receptor (PRR), while its soluble form sALCAM is involved in ALCAM-dependent and -independent immune mechanisms. The aim of this study was to investigate the effect of aggressive removal of low density lipoprotein-cholesterol (LDL-C) and lipoprotein(a) (Lp [a]) by lipoprotein-apheresis (LA) on sALCAM and blood viscosity as well as to evaluate its association with lipoproteins and serum markers of inflammation.

Key words

Atherosclerosis - inflammation - pattern recognition receptor - lipoproteins

Full Text

References

References
1 Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126
2 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874
3 Higashimori M, Tatro JB, Moore KJ. et al. Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31: 50-57
4 Gu JQ, Wang DF, Yan XG. et al. A Toll-like receptor 9-mediated pathway stimulates perilipin 3 (TIP47) expression and induces lipid accumulation in macrophages. Am J Physiol Endocrinol Metab 2010; 299: E593-E600
5 Takiwaki M, Tomoda F, Koike T. et al. Increased levels of small dense low-density lipoprotein cholesterol associated with hemorheological abnormalities in untreated, early-stage essential hypertensives. Hypertension Research 2014; 37: 1008-1013
6 Gemeinsamer-Bundesausschuss Bekanntmachung des Bundesauschusses der Ärzte und Krankenkassen über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Apherese bei isolierter Lp(a)-Erhöhung für Studienteilnehmer. BAnz 2003; 128: 3005
7 Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-2828
8 Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 1981; 2: 1005-1007
9 Krebs A, Krebs K, Keller F. Retrospective comparison of 5 different methods for long-term LDL-apheresis in 20 patients between 1986 and 2001. Int J Artif Organs 2004; 27: 137-148
10 Koziolek M, Hennig U, Zapf A. et al. Retrospective Analysis of Long-term Lipid Apheresis at a Single Center. Ther Apher Dial 2010; 14: 143-152
11 Stefanutti C, Morozzi C, Petta A. Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine 2011; 56: 842-849
12 Matsumoto A, Mitchell A, Kurata H. et al. Cloning and characterization of HB2, a candidate high density lipoprotein receptor. Sequence homology with members of the immunoglobulin superfamily of membrane proteins. J Biol Chem. 1997; 272: 16778-16782
13 von Bauer R, Oikonomou D, Sulaj A. et al. CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity. J Immunol 2013; 191: 369-377
14 Guerraty MA, Grant GR, Karanian JW. et al. Side-specific expression of activated leukocyte adhesion molecule (ALCAM; CD166) in pathosusceptible regions of swine aortic valve endothelium. J Heart Valve Dis 2011; 20: 165-167
15 Ikeda K, Quertermous T. Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem 2004; 279: 55315-55323
16 Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungsund Behandlungsmethoden der vertragsärztlichen Versorgung; Ambulante Durchführung der Apheresen als extrakorporales Hämotherapieverfahren. BAnz AT 2017
17 Oikonomou D, Kopf S, von Bauer R. et al. Influence of insulin and glargine on outgrowth and number of circulating endothelial progenitor cells in type 2 diabetes patients: A partially double-blind, randomized, three-arm unicenter study. Cardiovasc Diabetol 2014; 13: 137
18 Park JW, Merz M, Braun P. Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. Atherosclerosis 1998; 139: 401-409
19 Moriarty PM, Gibson CA, Shih J. et al. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 2001; 158: 495-498
20 Carbotti G, Orengo AM, Mezzanzanica D. et al. Activated leukocyte cell adhesion molecule soluble form: A potential biomarker of epithelial ovarian cancer is increased in type II tumors. Int J Cancer 2013; 132: 2597-2605
21 Hansen AG, Arnold SA, Jiang M. et al. ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Res 2014; 74: 1404-1415
22 Ikeda K, Quertermous T. Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem 2004; 279: 55315-55323
23 Rauch SJ, Rosenkranz AC, Böhm A. et al. Cholesterol induces apoptosis-associated loss of the activated leukocyte cell adhesion molecule (ALCAM) in human monocytes. Vascul Pharmacol 2011; 54: 93-99
24 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168
25 Bowen M, Patel D, Li X. et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 1995; 181: 2213-2220
26 Klingel R, Mumme C, Fassbender T. et al. Rheopheresis in patients with ischemic diabetic foot syndrome: Results of an open label prospective pilot trial. Ther Apher Dial 2003; 7: 444-455
27 Suckfüll M. Hearing Loss Study Group. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: A randomised multicentre trial. Lancet 2002; 360: 1811-1817
28 Tamai O, Matsuoka H, Itabe H. et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82